ClinicalTrials.gg
CompletedNCT00280397Updated Oct 7, 2016Results posted

An Open Label Phase I Dose Escalation Study of E7080 Administered to Patients With Solid Tumors

A Phase 1 interventional study of E7080 in Cancer: Solid Tumors, sponsored by Eisai Inc.. Completed at 1 site in Japan. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-10-07.

Sponsored by Eisai Inc. · Phase 1, Interventional, and Treatment

How we know · 4 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
27
Allocation
Not applicable
Ages
20 Years to 75 Years
Sex
All
01

Study summary

The purpose of this study is to determine the maximum tolerable dose (MTD) and the related effects of E7080 administered to patients with solid tumors that are resistant to approved existing anti-tumor therapies, or for which no appropriate treatment is available.

02

Conditions studied

  • Cancer: Solid Tumors

Browse trials for

Keywords

  • Cancer, solid tumors
03

In context

Neoplasms

10,834 studies on the registry are indexed under Neoplasms; 2,323 are open to participants now.

This study's enrollment of 27 is below the median of 60 across 7,714 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Eisai Inc. is the lead sponsor of 368 studies on the registry; 7 are open to participants now.

Of its 83 completed or terminated interventional studies of FDA-regulated products, 56 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients who have and/or cytologically confirmed solid tumors requiring treatment.
  2. Patients with solid tumors which are resistant to approved conventional anti-tumor therapies, or for which no appropriate treatment is available.
  3. Patients who had completed all previous treatments (including surgery and radiotherapy) and supportive care (such as transfusion of blood, blood components and granulocyte colony-stimulating factor [G-CSF] treatment) at least 4 weeks before registration, and no sign or symptom of acute toxicity occurred in previous treatments.
  4. Patients 20 years or older and less than 75 years of age at the time of registration.
  5. Patients with 0 or 1 Performance Status (PS) established by (ECOG.)
  6. Patients who can stay in hospital for more than 1 cycle of treatment.
  7. Patients who are expected to survive for more than 3 months from the start of study drug administration.
  8. Patients who have provided written for the participation in the study.

Exclusion criteria

Exclusion criteria:

  1. Patients with clinical symptoms due to requiring treatment.
  2. Patients who have any of the following laboratory test findings:

    1. less than 9.0 g/dL
    2. less than 1.5 x 10 9/L
    3. count less than 100 x 10 9/L
    4. Serum greater than 1.5 mg/dL
    5. , ALT greater than 100 IU/L
    6. Serum creatinine greater than 1.5 mg/dL or less than 50 mL/minute
  3. Patients with positive reaction for (HIV) or hepatitis virus C () antibody or virus surface (HBs) antigen, or patients with untreated serious infections.
  4. Patients with cardiac disorders or unstable ischemic heart diseases including myocardial infarction within six months before the registration for the study.
  5. Patients with marked Baseline prolongation of /QTc interval (QTc interval greater than 450 msec for males or greater than 470 msec for females) using the Fridericia method for QTc analysis.
  6. Patients with hemorrhagic or thrombotic diseases or who are using therapeutic doses of anticoagulants such as aspirin, warfarin, or ticlopidine.
  7. Patients who are diagnosed with hypertension (defined as repeatedly measured blood pressure = 160/90 mmHg) at Screening, irrespective of use of antihypertensive drugs.
  8. Patients who have proteinuria greater than 1 on bedside testing.
  9. Patients who have history of insufficient gastrointestinal absorption, or patients who received gastric or intestinal anastomoses within 4 weeks before registration.
  10. Patients who have history of alcoholism, drug addiction or mental or physical disorders, which, in the investigators opinion, may impair study compliance.
  11. Patients who received any drug within 30 days before the registration of the study.
  12. Patients who received inhibitors including itraconazole, erythromycin, clarithromycin, diltiazem or verapamil during screening and who have to use these drugs during the study.
  13. Pregnant or nursing patients (all female patients with pregnancy potential must have negative pregnancy test performed before registration, and women must be amenorrheic for at least 12 months.) Female patients must use appropriate .
  14. Fertile male patients who refuse to use contraception, or whose female partners are not using appropriate contraception.
  15. Patients who are judged by the investigator to be inappropriate for the study.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    1

    Drug: E7080

Interventions

  • DrugLenvatinibStudies of LenvatinibLenvatinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    E7080 is administered orally twice a day for 2 weeks to patients with solid tumors that are resistant to approved conventional therapies or for which no appropriate treatment is available.

06

What researchers measure

Primary outcomes

  1. Maximum Tolerable Dose (MTD) of E7080 Repeatedly Administered Twice a Day

    The MTD was defined as the highest dose at which no dose limiting toxicity (DLT) was experienced by the first 3 patients in that cohort, or the dose at which a DLT was experienced by no more than 1 of 6 patients evaluable for toxicity.

    Time frame: up to 4 weeks

  2. DLT of E7080 Repeatedly Administered Twice a Day

    DLTs were defined as grade 3 or more platelet count decrease, grade 4 neutropenia, any grade 3 or more nonhematologic toxicity (with exceptions of grade 4 hypertension not controlled by any antihypertensive drugs and grade greater than or equal to 3 vomiting and diarrhea not controlled by antiemetic or antidiarrheal drugs), and failure to administer more than 75% of the planned doses of E7080 during the same cycle due to toxicity.

    Time frame: up to 4 weeks

Secondary outcomes

  1. To Elucidate the Pharmacokinetic Profile of E7080

    Time frame: Every 3 weeks

  2. Number of Participants With Adverse Events / Serious Adverse Events

    Treatment emergent adverse events (AEs) and serious adverse events (SAEs) were evaluated.

    Time frame: Until tumor progression, unacceptable toxicity, or withdrawal due to other reasons.

  3. Determine the Clinical Dose for Phase II Study Based on Safety and Pharmacokinetic Profile

    Time frame: Every 3 weeks

  4. Evaluate the Anti-tumor Activity of E7080

    Time frame: Every 3 weeks

  5. To Make Exploratory Analyses of Pharmacodynamic Markers

    Time frame: Every 3 weeks

07

Results

Posted Mar 6, 2015

Participant flow

Participant flow — Overall Study
MilestoneE7080 Group
Started27
Completed26
Not completed1
Withdrew: Adverse event1

Outcome measures

SecondaryTo Elucidate the Pharmacokinetic Profile of E7080
Time frame:
Every 3 weeks

Results for this outcome have not been posted.

PrimaryMaximum Tolerable Dose (MTD) of E7080 Repeatedly Administered Twice a Day

The MTD was defined as the highest dose at which no dose limiting toxicity (DLT) was experienced by the first 3 patients in that cohort, or the dose at which a DLT was experienced by no more than 1 of 6 patients evaluable for toxicity.

Time frame:
up to 4 weeks
Reported as:
Number · mg BID
Maximum Tolerable Dose (MTD) of E7080 Repeatedly Administered Twice a Day
mg BIDE7080 Group
Maximum Tolerable Dose (MTD) of E7080 Repeatedly Administered Twice a Day13
SecondaryNumber of Participants With Adverse Events / Serious Adverse Events

Treatment emergent adverse events (AEs) and serious adverse events (SAEs) were evaluated.

Time frame:
Until tumor progression, unacceptable toxicity, or withdrawal due to other reasons.
Reported as:
Number · Participants
Number of Participants With Adverse Events / Serious Adverse Events
ParticipantsE7080 Group
Number of Participants With Adverse Events / Serious Adverse Events27
PrimaryDLT of E7080 Repeatedly Administered Twice a Day

DLTs were defined as grade 3 or more platelet count decrease, grade 4 neutropenia, any grade 3 or more nonhematologic toxicity (with exceptions of grade 4 hypertension not controlled by any antihypertensive drugs and grade greater than or equal to 3 vomiting and diarrhea not controlled by antiemetic or antidiarrheal drugs), and failure to administer more than 75% of the planned doses of E7080 during the same cycle due to toxicity.

Time frame:
up to 4 weeks
Reported as:
Number · Participants with DLT
DLT of E7080 Repeatedly Administered Twice a Day
Participants with DLTE7080 - 16 mg GroupE7080 - 20 mg Group
DLT of E7080 Repeatedly Administered Twice a Day12
SecondaryDetermine the Clinical Dose for Phase II Study Based on Safety and Pharmacokinetic Profile
Time frame:
Every 3 weeks

Results for this outcome have not been posted.

SecondaryEvaluate the Anti-tumor Activity of E7080
Time frame:
Every 3 weeks

Results for this outcome have not been posted.

SecondaryTo Make Exploratory Analyses of Pharmacodynamic Markers
Time frame:
Every 3 weeks

Results for this outcome have not been posted.

Adverse events

Collected over Until tumor progression, unacceptable toxicity, or withdrawal due to other reasons.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
E7080 Group—7/27 (25.9%)27/27 (100%)
Most frequent serious events
Most frequent serious events
EventE7080 Group
HypertensionVascular disorders2/27
Postrenal failureRenal and urinary disorders1/27
HaemorrhageVascular disorders1/27
PneumoniaInfections and infestations1/27
DyspnoeaRespiratory, thoracic and mediastinal disorders1/27
Platelet count decreasedInvestigations1/27
Humerus fractureInjury, poisoning and procedural complications1/27
Most frequent other events
Showing 10 of 84
Most frequent other events
EventE7080 Group
Blood urine presentInvestigations20/27
FatigueGeneral disorders19/27
Aspartate aminotransferase increasedInvestigations17/27
Protein urine presentInvestigations17/27
HeadacheNervous system disorders17/27
HypertensionVascular disorders17/27
DiarrhoeaGastrointestinal disorders15/27
Alanine aminotransferase increasedInvestigations15/27
Blood lactate dehydrogenase increasedInvestigations14/27
Blood albumin decreasedInvestigations13/27

Baseline characteristics

Age, Continuous
Age, Continuous(Years)E7080 Group
Mean50.7 ± 11.1
Sex/Gender, Customized
Sex/Gender, Customized(Participants)E7080 Group
Male10
Female17
08

Study locations

1 site
  • Tokyo, 104-0045, Japan
09

References and documents

Publications

  • Koyama N, Saito K, Nishioka Y, Yusa W, Yamamoto N, Yamada Y, Nokihara H, Koizumi F, Nishio K, Tamura T. Pharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib. BMC Cancer. 2014 Jul 21;14:530. doi: 10.1186/1471-2407-14-530. PubMed 25047123 ↗
  • Yamada K, Yamamoto N, Yamada Y, Nokihara H, Fujiwara Y, Hirata T, Koizumi F, Nishio K, Koyama N, Tamura T. Phase I dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumors. Clin Cancer Res. 2011 Apr 15;17(8):2528-37. doi: 10.1158/1078-0432.CCR-10-2638. Epub 2011 Mar 3. PubMed 21372218 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2006, a primary completion of Sep 2008 and a completion of Nov 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2015, 6 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2006
First posted
Jan 23, 2006
Start
Jan 2006
Primary completionActual
Sep 2008
CompletionActual
Nov 2008
Results first posted
Mar 6, 2015
Last update
Oct 7, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 7, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00280397
Lead sponsor
Eisai Inc.
Responsible party
Sponsor
First posted
Jan 23, 2006
Start date
Jan 2006
Primary completion
Sep 2008
Completion
Nov 2008
Results posted
Mar 6, 2015
Last update
Oct 7, 2016

Study contacts

Akihiko Tsuruoka
study director · Eisai Co., Ltd.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenvatinib

Start the discussion